Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) traded up 13.6% during trading on Wednesday. The stock traded as high as $8.68 and last traded at $8.7350. 729,159 shares were traded during trading, a decline of 49% from the average daily volume of 1,426,370 shares. The stock had previously closed at $7.69.
REGENXBIO News Summary
These are some of the RGNX news items that stood out recently:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.15 from a loss of $3.65, while maintaining its Buy rating. REGENXBIO analyst coverage
- Neutral Sentiment: A short-interest update reports zero shares sold short and zero days to cover, despite describing a “significant increase.” The conflicting wording makes the data difficult to interpret and does not provide a clear directional signal.
- Negative Sentiment: HC Wainwright lowered EPS estimates for Q4 2026 and each quarter of 2027, and cut its FY2027 estimate to a loss of $4.41 from $4.02. The deeper projected losses may weigh on sentiment, although the firm retained its Buy rating. REGENXBIO analyst coverage
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on RGNX. Mizuho set a $18.00 price objective on shares of REGENXBIO in a research note on Friday, November 6th. Zacks Research upgraded shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings upgraded shares of REGENXBIO from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Wall Street Zen downgraded shares of REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Morgan Stanley reissued an “overweight” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and an average price target of $23.18.
View Our Latest Research Report on RGNX
REGENXBIO Price Performance
The firm’s 50 day moving average price is $7.74 and its 200-day moving average price is $8.98. The firm has a market cap of $571.47 million, a price-to-earnings ratio of -2.70 and a beta of 1.24.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.67. REGENXBIO had a negative net margin of 113.85% and a negative return on equity of 203.98%. The firm had revenue of $9.16 million during the quarter, compared to analysts’ expectations of $10.89 million. Analysts expect that REGENXBIO Inc. will post -3.10 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in RGNX. BlackRock Inc. bought a new stake in shares of REGENXBIO in the second quarter valued at about $76,641,000. Dimensional Fund Advisors LP increased its stake in REGENXBIO by 11.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,010,381 shares of the biotechnology company’s stock valued at $8,464,000 after acquiring an additional 106,530 shares during the period. Bank of America Corp DE acquired a new position in REGENXBIO in the 2nd quarter valued at approximately $6,212,000. Corient Private Wealth LP acquired a new position in REGENXBIO in the 2nd quarter valued at approximately $2,608,000. Finally, Deutsche Bank AG acquired a new position in REGENXBIO in the 2nd quarter valued at approximately $2,490,000. Institutional investors and hedge funds own 88.08% of the company’s stock.
REGENXBIO Company Profile
REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for inherited diseases and other serious conditions. Founded in 2008 and headquartered in Rockville, Maryland, the company uses its proprietary NAV AAV gene-delivery platform to develop treatments intended to deliver genetic material to patients’ cells. Its research programs have included RGX-314, an investigational gene therapy for retinal diseases such as wet age-related macular degeneration, and candidates for conditions including Hunter syndrome and Duchenne muscular dystrophy.
Featured Articles
- Five stocks we like better than REGENXBIO
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
- Why Apple Stock Looks Like a Safe Haven After the Midterms
- IonQ Raised the Bar, But 3 Quantum Rivals Face Tough Questions
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
